Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1771 to 1785 of 7707 results

  1. Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]

    Suggested remit: To appraise the clinical and cost effectiveness of natalizumab within its marketing authorisation for treating highly active relapsing-remittin...

    Technology appraisal guidance
    Topic selection

  2. OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

    Awaiting development [GID-HST10022] Expected publication date: TBC

    Highly specialised technologies guidance
    Awaiting development

  3. Canakinumab for untreated Schnitzler syndrome [ID4063]

    Suggested remit: To appraise the clinical and cost effectiveness of canakinumab within its marketing authorisation for treating Schnitzler syndrome. ...

    Technology appraisal guidance
    Topic selection

  4. STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]

    Awaiting development [GID-TA10279] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Rivaroxaban for treating chronic heart failure [ID1462]

    Awaiting development [GID-TA10393] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]

    In development [GID-TA10919] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]

    In development [GID-TA10998] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237

    Awaiting development [GID-TA11328] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Levodopa, carbidopa monohydrate and entacapone intestinal gel for treating the symptoms of advanced Parkinson's disease [ID4005]

    Suggested remit: To appraise the clinical and cost effectiveness of levodopa, carbidopa monohydrate and entacapone within its marketing authorisation for treati...

    Technology appraisal guidance
    Topic selection

  10. Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide TS ID 10046

    Awaiting development [GID-TA11335] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Bimekizumab for treating ankylosing spondylitis TS ID 10334

    Awaiting development [GID-TA11150] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 TS ID 11848

      Status ...

    Technology appraisal guidance
    Topic selection

  13. Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592

    Awaiting development [GID-TA11332] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over TS ID 9130

    Awaiting development [GID-TA11325] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Galcanezumab for migraine TS ID 10663

    Awaiting development [GID-TA11311] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development